Babraham Research Campus

Babraham Research Campus

The Babraham Research Campus is considered to be the UK’s leading campus to support early-stage bioscience enterprise. World class research and business come together to promote innovation and strengthen links between academia and the commercial world.

Telephone: +44 (0)1223 496 000
Address: Babraham Bioscience Technologies, Babraham Research Campus, Babraham
Postcode: CB22 3AT
Country: United Kingdom
Website: http://www.babraham.com/
Membership type:Cambridge University Department

Our mission is simple.

We will be the best place in Europe to start-up and scale-up a life science business.  Our aim is to create an environment where companies can focus on developing their science and building their business in a supportive and highly networked community, helping to create new medicines, jobs and growth, and maximising the impact of UK science.

Investors invited to discover the next big thing in life science and med-tech

Now in its 10th year, the one-day Babraham Investor Conference (BIC) will bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities across the UK and Europe.

25 March 2019Read in full

PredictImmune wins Business Weekly Life Science Innovation (Product) award

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to have been awarded the Life Science Innovation award for product development at the annual Business Weekly awards.

21 March 2019Read in full

ImmunoBiology Ltd enters licensing agreement with China's largest vaccine producer

Cambridge-based vaccine company ImmunoBiology Ltd (ImmBio) has entered a licensing agreement with the largest vaccine producer in China, CNBG, to co-develop ImmBio’s PnuBioVax Vaccine against pneumococcal infection.

19 March 2019Read in full

Derek Jones

Apply to present at the 2019 Babraham Investor Conference

The Babraham Investor Conference (BIC) is back to bring together like-minded investors focused on early-stage and scale-up life science and med-tech opportunities. Now, companies seeking funding of between £250K to £20M have the opportunity to pitch to an audience of potential investors on 15 May at the Babraham Research Campus, Cambridge.

18 March 2019Read in full

Paul Kinnon, CEO, PredictImmune

PredictImmune's first product enters NICE Diagnostic Assessment Programme

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the formal entry of its first product, PredictSURE IBD™, into NICE’s Diagnostic Assessment Programme (DAP).

12 March 2019Read in full

Babraham Hall

Applications open for second Accelerate@Babraham life-science start-up competition

Life science start-ups are invited to apply for the opportunity to win access to the Babraham Research Campus bio-incubator facilities, plus an extended programme of support and mentoring.

6 March 2019Read in full

Paul Kinnon

PredictImmune announces issuance of new US patent in support of commercialisation

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed its latest patent grant in the US. The US patent is part of PredictImmune’s third family of intellectual property (IP) relating to methods for predicting autoimmune disease risk.

26 February 2019Read in full

Mission Therapeutics appoints Dr Nick Edmunds to VP, Head of DUB Discovery

Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect.

4 December 2018Read in full

Paul Kinnon, CEO

PredictImmune and the Crohn’s & Colitis Foundation announce a joint study

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation. The study is expected to advance progress towards personalised medicine for inflammatory bowel disease (IBD) patients in the US.

4 December 2018Read in full

Mission Therapeutics and AbbVie sign DUBs collaboration in Alzheimer’s and Parkinson’s

Collaboration combines Mission’s unique science, chemistry and proprietary enzyme platform with AbbVie’s strong neurodegenerative disease research, development and commercialisation capabilities

15 November 2018Read in full

  1. 1
  2. 2